Litcius/Paper detail

Implementing cell-free DNA of pancreatic cancer patient–derived organoids for personalized oncology

Zahra Dantes, Hsi-Yu Yen, Nicole Pfarr, Christof Winter, Katja Steiger, Alexander Muckenhuber, Alexander Hennig, Sebastian Lange, Thomas Engleitner, Rupert Öllinger, Roman Maresch, Felix Orben, Irina Heid, Georgios Kaissis, Kuangyu Shi, Geoffrey J. Topping, Fabian Stögbauer, Matthias Wirth, Katja Peschke, Aristeidis Papargyriou, Massoud Rezaee-Oghazi, Karin Feldmann, Arlett Schäfer, Raphela A. Ranjan, Clara Lubeseder–Martellato, Daniel E. Stange, Thilo Welsch, Marc E. Martignoni, Güralp O. Ceyhan, Helmut Frieß, Alexander Herner, Lucia Liotta, Matthias Treiber, Guido von Figura, Mohamed Abdelhafez, Peter Klare, Christoph Schlag, Hana Algül, Jens T. Siveke, Rickmer Braren, Gregor Weirich, Wilko Weichert, Dieter Saur, Roland Rad, Roland M. Schmid, Günter Schneider, Maximilian Reichert

2020JCI Insight49 citationsDOIOpen Access PDF

Abstract

One of the major challenges in using pancreatic cancer patient-derived organoids (PDOs) in precision oncology is the time from biopsy to functional characterization. This is particularly true for endoscopic ultrasound-guided fine-needle aspiration biopsies, typically resulting in specimens with limited tumor cell yield. Here, we tested conditioned media of individual PDOs for cell-free DNA to detect driver mutations already early on during the expansion process to accelerate the genetic characterization of PDOs as well as subsequent functional testing. Importantly, genetic alterations detected in the PDO supernatant, collected as early as 72 hours after biopsy, recapitulate the mutational profile of the primary tumor, indicating suitability of this approach to subject PDOs to drug testing in a reduced time frame. In addition, we demonstrated that this workflow was practicable, even in patients for whom the amount of tumor material was not sufficient for molecular characterization by established means. Together, our findings demonstrate that generating PDOs from very limited biopsy material permits molecular profiling and drug testing. With our approach, this can be achieved in a rapid and feasible fashion with broad implications in clinical practice.

Topics & Concepts

Pancreatic cancerBiopsyOrganoidFine-needle aspirationPersonalized medicineWorkflowLiquid biopsyCell-free fetal DNAMedicineClinical OncologyInternal medicineCancerOncologyComputational biologyCancer researchBioinformaticsBiologyComputer scienceGeneticsPregnancyPrenatal diagnosisDatabaseFetusPancreatic and Hepatic Oncology ResearchCancer Genomics and DiagnosticsRenal and related cancers
Implementing cell-free DNA of pancreatic cancer patient–derived organoids for personalized oncology | Litcius